LB Pharmaceuticals Downside Variance
| LBRX Stock | | | 23.53 -0.46 -1.92% |
Technical inputs supporting the Downside Variance indicator for LB Pharmaceuticals Common are shown here. The information is based on observed market data across timeframes. LB Pharmaceuticals has a market cap of 595.29 M. Allocation context is available in
Correlation Analysis. Portfolio composition is shown for contextual purposes. The summary draws on available position and value data. This information is provided for contextual purposes. This suggests a position in LB Pharmaceuticals Common. This appears in the portfolio view. Position weights are derived from the portfolio construction methodology. This overview is based on available data and does not express a directional view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in main economic indicators.
LB Pharmaceuticals Common has current Downside Variance of 14.77. Downside Variance (or DV) is measured by target semi-variance and is termed downside volatility. It is expressed in percentages and therefore allows for rankings in the same way as variance. One way to view downside volatility is the annualized variance of returns below the target.
Downside Variance | = | SUM(RET DEV)2N(ER) |
| = | 14.77 | |
| SUM | = | Summation notation |
| RET DEV | = | Actual returns deviation over selected period |
| N(ER) | = | Number of points with returns less than expected return for the period |
Downside Variance Peers Comparison
Downside Variance Relative To Other Indicators
LB Pharmaceuticals Common is rated
below average in downside variance among leading competitors. It is currently under evaluation in maximum drawdown among leading competitors reporting about
1.38 of Maximum Drawdown per Downside Variance. At
1.38 , LB Pharmaceuticals Common's Maximum Drawdown-to-Downside Variance multiple reflects the spread between these metrics
Downside Variance is the probability-weighted squared below-target returns. The squaring of the below-target returns has the effect of penalizing failures at an exponential rate. This is consistent with observations made on the behavior of individual decision-making under.
Compare LB Pharmaceuticals to Peers
Other Technical Indicators